NASDAQ:ITCI

Intra-Cellular Therapies - ITCI Stock Forecast, Price & News

$45.78

+0.17 (+0.37%)

(As of 03/23/2023 01:27 PM ET)

Add

Compare

Today's Range: $45.39
▼
$46.71
50-Day Range: $43.80
▼
$50.01
52-Week Range: $42.01
▼
$66.00

Volume: 144,999 shs
Average Volume: 706,028 shs
Market Capitalization: $4.36 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $69.40

Institutional Ownership

Intra-Cellular Therapies MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.78 Rating Score
Upside/Downside: 51.6% Upside
$69.40 Price Target
Short Interest: Bearish
3.47% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.23
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$11.75 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.43) to ($1.14) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

325th out of 986 stocks

Pharmaceutical Preparations Industry

143rd out of 477 stocks

3.4

Analyst's Opinion

Consensus Rating
Intra-Cellular Therapies has received a consensus rating of Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $69.40, Intra-Cellular Therapies has a forecasted upside of 51.6% from its current price of $45.78.
Amount of Analyst Coverage
Intra-Cellular Therapies has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
3.47% of the outstanding shares of Intra-Cellular Therapies have been sold short.
Short Interest Ratio / Days to Cover
Intra-Cellular Therapies has a short interest ratio ("days to cover") of 5.
Change versus previous month
Short interest in Intra-Cellular Therapies has recently increased by 37.92%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Intra-Cellular Therapies does not currently pay a dividend.
Dividend Growth
Intra-Cellular Therapies does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Intra-Cellular Therapies has received a 69.69% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is mostly driven by its "Antipsychotics", "Clinical research services for mood disorders", and "Clinical research services for substance abuse disorders " products. See details.
Environmental Sustainability
The Environmental Impact score for Intra-Cellular Therapies is -1.23.

1.9

News and Social Media Coverage

News Sentiment
Intra-Cellular Therapies has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Intra-Cellular Therapies this week, compared to 2 articles on an average week.
Search Interest
3 people have searched for ITCI on MarketBeat in the last 30 days.
MarketBeat Follows
Only 1 people have added Intra-Cellular Therapies to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Intra-Cellular Therapies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,749,484.00 in company stock.
Percentage Held by Insiders
Only 3.70% of the stock of Intra-Cellular Therapies is held by insiders.
Percentage Held by Institutions
86.95% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($2.43) to ($1.14) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Intra-Cellular Therapies is -16.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Intra-Cellular Therapies is -16.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Intra-Cellular Therapies has a P/B Ratio of 6.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Intra-Cellular Therapies (NASDAQ:ITCI) Stock

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm's lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.

Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

ITCI Stock News Headlines

March 19, 2023 | americanbankingnews.com

Comparing Intra-Cellular Therapies (NASDAQ:ITCI) & Pacira BioSciences (NASDAQ:PCRX)

March 16, 2023 | americanbankingnews.com

Suresh K. Durgam Sells 7,344 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stock

March 23, 2023 | Stansberry Research (Ad)

The gold catalyst we’ve waited for

If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.